ESC Premium Access

Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial

Congress Session

About the speaker

Doctor Matthew Segar

University of Texas Southwestern Medical Center, Dallas (United States of America)
0 follower

4 more presentations in this session

Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies.

Speaker: Professor M. Banach (Lodz, PL)

Thumbnail

Impact of early initiation of SGLT2 inhibitor on cardiovascular outcomes in diabetic patients with known atherosclerotic cardiovascular disease or risk factors: propensity score matched analysis

Speaker: Doctor W. Sun (Shatin, HK)

Thumbnail

Changes in EPA and DHA during supplementation with Omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial

Speaker: Doctor P. Myhre (Akershus, NO)

Thumbnail

Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial

Speaker: Doctor F. Cosentino (Stockholm, SE)

Thumbnail

Access the full session

Can we improve outcomes by targeting metabolic risk?

Speakers: Doctor M. Segar, Professor M. Banach, Doctor W. Sun, Doctor P. Myhre, Doctor F. Cosentino
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

This platform is supported by

logo Novo Nordisk